These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22534502)

  • 41. Heterotopic ossification following distal radius fractures in a patient with Parkinson disease treated with levodopa-carbidopa.
    Ifedi BO; Best CM; Reichel LM
    J Hand Surg Am; 2013 Jun; 38(6):1259-61. PubMed ID: 23707023
    [No Abstract]   [Full Text] [Related]  

  • 42. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
    Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X
    Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients.
    Schneider E; Hubener K; Fischer PA
    Adv Neurol; 1984; 40():527-9. PubMed ID: 6695631
    [No Abstract]   [Full Text] [Related]  

  • 44. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.
    LeWitt PA; Jennings D; Lyons KE; Pahwa R; Rabinowicz AL; Wang J; Guarnieri M; Hubble JP; Murck H
    Mov Disord; 2009 Jul; 24(9):1319-24. PubMed ID: 19412946
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sinemet CR in Parkinson's disease.
    Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
    Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current and future approaches to therapy.
    Birkmayer W; Birkmayer JD
    Adv Neurol; 1987; 45():511-2. PubMed ID: 3103393
    [No Abstract]   [Full Text] [Related]  

  • 47. A case of severe leg oedema in a patient with Parkinson's disease treated with pramipexole.
    Cicero CE; Nicoletti A; Mostile G; Zappia M
    Postgrad Med J; 2016 Aug; 92(1090):484. PubMed ID: 26941267
    [No Abstract]   [Full Text] [Related]  

  • 48. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
    Peppe A; Dambrosia JM; Chase TN
    Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213
    [No Abstract]   [Full Text] [Related]  

  • 49. What to do when Sinemet fails: Part one.
    Klawans HL
    Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
    [No Abstract]   [Full Text] [Related]  

  • 50. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
    Fernandez HH; Odin P
    Curr Med Res Opin; 2011 May; 27(5):907-19. PubMed ID: 21351823
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low CSF GABA in Parkinsonian patients who respond poorly to therapy or suffer from the "on-off" phenomenon.
    Teychenné PF; Ziegler MG; Lake CR; Enna SJ
    Ann Neurol; 1982 Jan; 11(1):76-9. PubMed ID: 6120678
    [No Abstract]   [Full Text] [Related]  

  • 52. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Motor deficits in Parkinsonian reaching: dopa-sensitivity influenced by real-world task constraint.
    Doan J; Whishaw IQ; Pellis SM; Suchowersky O; Brown LA
    J Mot Behav; 2006 Jan; 38(1):45-59. PubMed ID: 16436362
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL; Schmitt L; Bagheri H
    Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Continuous dopaminergic stimulation in Parkinson disease: possibilities in 2013].
    Aschermann Z; Kovács N; Komoly S
    Ideggyogy Sz; 2013 May; 66(5-6):209-10. PubMed ID: 23909024
    [No Abstract]   [Full Text] [Related]  

  • 56. Several classes of new drugs emerging for Parkinson disease.
    Phillips P
    JAMA; 1999 Sep; 282(10):929-31. PubMed ID: 10485664
    [No Abstract]   [Full Text] [Related]  

  • 57. New options for treatment of Parkinson's disease.
    LeWitt PA
    Baillieres Clin Neurol; 1997 Apr; 6(1):109-23. PubMed ID: 9426871
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medical hazards of the internet: gambling in Parkinson's disease.
    Larner AJ
    Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457
    [No Abstract]   [Full Text] [Related]  

  • 59. Current pharmacotherapeutic treatment options in Parkinson's disease.
    Rezak M
    Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improving quality of life in early Parkinson's.
    Health News; 2005 Feb; 11(2):2. PubMed ID: 15732144
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.